Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the ana

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --  -- ELE

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy a

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committ

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Ther

LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o

Entrada Therapeutics NASDAQ: TRDA said initial data from the first cohort of its phase I/II ELEVATE-

Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See wh

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA)

Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US

Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to n

Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despit

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the ana

Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outper

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the ana

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)

-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 ---- Co

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Entrada Therapeutics (NASDAQ:TRDA)

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-20

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the a

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.42) per share which beat the ana

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)

ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $0.03 per share which beat the ana

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-

"Given the strength of our safety and target engagement data from our Phase 1 clinical study and

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the Unit